Engineering chimeric antigen receptors

S. V. Kulemzin; V. V. Kuznetsova; M. Mamonkin; A. V. Taranin; A. A. Gorchakov

doi:10.32607/20758251-2017-9-1-6-14

Engineering chimeric antigen receptors

S. V. Kulemzin, V. V. Kuznetsova, M. Mamonkin, A. V. Taranin, A. A. Gorchakov

Лаборатория структурной, функциональной и сравнительной геномики ФЕН

Результат исследования: Научные публикации в периодических изданиях › обзорная статья › рецензирование

9 Цитирования (Scopus)

Аннотация

Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering.

Язык оригинала	английский
Страницы (с-по)	6-14
Число страниц	9
Журнал	Acta Naturae
Том	9
Номер выпуска	1
DOI	https://doi.org/10.32607/20758251-2017-9-1-6-14
Состояние	Опубликовано - 1 янв 2017

Доступ к документу

10.32607/20758251-2017-9-1-6-14

Link to publication in Scopus

Цитировать

@article{225b1fa9dfd546e4b016ba72173268e0,

title = "Engineering chimeric antigen receptors",

abstract = "Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering.",

keywords = "Adoptive immunotherapy, Cancer, Chimeric antigen receptor, T cells",

author = "Kulemzin, {S. V.} and Kuznetsova, {V. V.} and M. Mamonkin and Taranin, {A. V.} and Gorchakov, {A. A.}",

year = "2017",

month = jan,

day = "1",

doi = "10.32607/20758251-2017-9-1-6-14",

language = "English",

volume = "9",

pages = "6--14",

journal = "Acta Naturae",

issn = "2075-8251",

publisher = "Park Media Ltd.",

number = "1",

}

Engineering chimeric antigen receptors. / Kulemzin, S. V.; Kuznetsova, V. V.; Mamonkin, M.; Taranin, A. V.; Gorchakov, A. A.

В: Acta Naturae, Том 9, № 1, 01.01.2017, стр. 6-14.

Результат исследования: Научные публикации в периодических изданиях › обзорная статья › рецензирование

TY - JOUR

T1 - Engineering chimeric antigen receptors

AU - Kulemzin, S. V.

AU - Kuznetsova, V. V.

AU - Mamonkin, M.

AU - Taranin, A. V.

AU - Gorchakov, A. A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering.

AB - Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering.

KW - Adoptive immunotherapy

KW - Cancer

KW - Chimeric antigen receptor

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85017535471&partnerID=8YFLogxK

U2 - 10.32607/20758251-2017-9-1-6-14

DO - 10.32607/20758251-2017-9-1-6-14

M3 - Review article

AN - SCOPUS:85017535471

VL - 9

SP - 6

EP - 14

JO - Acta Naturae

JF - Acta Naturae

SN - 2075-8251

IS - 1

ER -

Engineering chimeric antigen receptors

Аннотация

Доступ к документу

Fingerprint

Цитировать